Biography
Dr. Edward Yardeni

Dr. Ed Yardeni is the President of Yardeni Research, Inc., a provider of global investment strategy and asset allocation analyses and recommendations. He previously served as Chief Investment Strategist of Oak Associates, Prudential Equity Group, and Deutsche Bank’s US equities division in New York City. He was also the Chief Economist of CJ Lawrence, Prudential-Bache Securities, and EF Hutton. He taught at Columbia University’s Graduate School of Business and was an economist with the Federal Reserve Bank of New York. He also held positions at the Federal Reserve Board of Governors and the US Treasury Department in Washington, D.C.

Dr. Ed earned his PhD in economics from Yale University in 1976, having completed his doctoral dissertation under Nobel Laureate James Tobin. Previously, he received a master’s degree in international relations from Yale. He completed his undergraduate studies magna cum laude at Cornell University.

Dr. Ed is frequently quoted in the financial press, including The Wall Street Journal, the Financial Times, The New York Times, The Washington Post, and Barron’s. He was dubbed Wall Street Seer in a Barron’s cover story. He appears frequently on CNBC and Bloomberg Television. See Dr. Ed’s Media Center blog.

In 2018, Dr. Ed published Predicting the Markets: A Professional Autobiography, which is rated 4.4/5.0 on Amazon with 93 reviews. In this book, he shares his unique insights into predicting the trends and cycles in the domestic and global economies and financial markets—including stocks, bonds, commodities, and currencies—based on the first 40 years of his career on Wall Street.

In 2020, Dr. Ed published Fed Watching for Fun & Profit, which is rated 5.0/5.0 by five reviewers. In this guide, Dr. Ed, one of the world’s most experienced and widely followed “Fed watchers,” helps investors to understand the FOMC’s decision-making process, anticipate its moves, and profit from those insights. Dr. Ed is one of LinkedIn’s 2019 Top Voices in economy & finance. Institutional investors may sign-up for a complimentary trial of his research service. Sign up to follow his LinkedIn Newsletter.